Forsinkede kurser. Sist oppdatert: søndag 21. april  

24/01-2019 16:40:15: (NANO) Nordic Nanovector launches a private placement of new shares

Not for general release, publication or distribution, directly or indirectly, in
the United States of America, Canada, Japan or Australia


Oslo, Norway, 24 January 2019

Nordic Nanovector ASA (OSE: NANO) ("Nordic Nanovector" or the "Company"), a
biopharmaceutical company dedicated to extending and improving the lives of
patients with haematological cancers through the development and
commercialisation of innovative targeted therapeutics, announces the launch of a
private placement of new shares representing up to approximately 10% (the "Offer
Shares") of the outstanding share capital of the company (the "Private
Placement"). DNB Markets and Jefferies International Limited are acting as Joint
Global Coordinators and Joint Bookrunners (the "Joint Global Coordinators"), and
Kempen & Co N.V. is acting as Joint Bookrunner (together with the Joint Global
Coordinators, the "Joint Bookrunners") in connection with the Private Placement.

Nordic Nanovector intends to use the net proceeds of the Private Placement for
the following purposes:

  ·  Manufacturing development activities (including Process Validation studies)
for Betalutin®
  · A scale-up of the Company's clinical and commercial activities in
preparation for a commercial launch of Betalutin®
  · General corporate purposes

The subscription price and the number of shares to be issued in the Private
Placement will be determined through an accelerated bookbuilding process. The
bookbuilding period and the application period for the Private Placement
commence today at 16:30 hours CET and will close at 08:00 hours CET on 25
January 2019 (the "Application Period"). The Company and the Joint Bookrunners
reserve the right to close or extend the Application Period at any time and for
any reason. If the Application Period is shortened or extended, any other dates
referred to herein may be amended accordingly.

The Company's largest shareholder, HealthCap VI L.P., has informed the Company
that it will participate in the Private Placement.

The minimum subscription and allocation amount in the Private Placement will be
the NOK equivalent of EUR 100,000, provided that the Company may, at its sole
discretion, allocate an amount below EUR 100,000 to the extent applicable
exemptions from the prospectus requirement pursuant to applicable regulations,
including the Norwegian Securities Trading Act and ancillary regulations, are
available. Allocation of the Offer Shares will be determined at the end of the
bookbuilding process, and the final allocation will be made by the Company's
Board of Directors at its sole discretion, following advice from the Joint

The Offer Shares to be issued in connection with the Private Placement will be
issued based on the board authorisation granted at the Company's annual general
meeting on 30 May 2018. In line with the shareholders' approval, pre-emption
rights of the existing shareholders are excluded.

The board of directors of the Company has considered alternative structures for
the raising of new equity. Following careful considerations, the board of
directors is of the view that the conduct of a private placement because this
will, inter alia, strengthen the Company's shareholder base in future equity
raisings. Furthermore, by structuring the transaction as a private placement,
the Company will be in a position to raise capital in an efficient manner in a
market that is open for capital raisings, and with a lower discount to current
trading price and with significantly lower risks compared to a rights issue. In
addition, the Private Placement is subject to broad marketing through a pre
-sounding and a publicly announced bookbuilding process. By this, a market based
subscription price will be achieved.

The board of directors therefore considers a private placement to be in the best
interests of the Company and its shareholders.

The Private Placement will be directed towards Norwegian and international
investors, in each case subject to and in compliance with applicable exemptions
from relevant prospectus or registration requirements. Notification of allotment
and payment instructions is expected to be issued to the applicants on or about
25 January 2019 through a notification to be issued by the Joint Bookrunners.

The Offer Shares will be settled with existing and unencumbered shares in the
Company that are already listed on the Oslo Stock Exchange, pursuant to a share
lending agreement between DNB Markets (on behalf of the Joint Bookrunners), the
Company and HealthCap VI L.P., in order to facilitate delivery of listed shares
to investors on a delivery versus payment basis. The Offer Shares delivered to
the subscribers will thus be tradable from allocation. The Joint Bookrunners
will settle the share loan with new shares in the Company to be issued by the
Board of Directors pursuant to the abovementioned authorisation granted at the
annual general meeting held on 30 May 2018.

The Company has agreed with the Joint Bookrunners to a lock-up on future share
issuances, and its Board of Directors and Executive Management have all agreed
with the Joint Bookrunners to a lock-up on existing shareholdings for a period
of 180 days from the closing date, subject to customary exceptions. In addition,
the Company's largest shareholder, HealthCap VI L.P. has agreed with the Joint
Bookrunners to a lock-up for a period of 90 days from the closing date, subject
to customary exceptions.

The Company will announce the final number of Offer Shares placed and the final
subscription price in the Private Placement in a stock exchange announcement
expected to be published before opening of trading on the Oslo Stock Exchange
tomorrow, 25 January 2019. Completion of the Private Placement is subject to
final approval by the Company's Board of Directors.

For further information, please contact:

Eduardo Bravo, CEO

Cell: +34 609 481 091


Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762


International Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571


About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain
marketing rights and to actively participate in the commercialisation of
Betalutin® in core markets. Further information can be found at

This information is subject to a duty of disclosure pursuant to Section 5-12 of
the Norwegian Securities Trading Act.

Important Notices

This document is not an offer to sell or a solicitation of offers to purchase or
subscribe for shares. Copies of this document may not be sent to jurisdictions,
or distributed in or sent from jurisdictions, in which this is barred or
prohibited by law. The information contained herein shall not constitute an
offer to sell or the solicitation of an offer to buy, in any jurisdiction in
which such offer or solicitation would be unlawful absent registration, or an
exemption from registration or qualification under the securities laws of any

This document is not for publication or distribution in the United States of
America, Canada, Australia or Japan and it does not constitute an offer or
invitation to subscribe for or purchase any securities in such countries or in
any other jurisdiction. In particular, the document and the information
contained herein should not be distributed or otherwise transmitted into the
United States of America or to U.S. persons (as defined in the U.S. Securities
Act of 1933, as amended (the "Securities Act")) or to publications with a
general circulation in the United States of America. This document is not an
offer for sale of securities in the United States of America. The securities
referred to herein have not been and will not be registered under the Securities
Act, or the laws of any state, and may not be offered or sold in the United
States of America absent registration under or an exemption from registration
under the Securities Act. Nordic Nanovector does not intend to register any part
of the Private Placement in the United States of America.

There will be no public offering of the securities in the United States of
America. Any public offering in the United States of America would be made by
means of a prospectus containing detailed information about the company and
management, as well as financial statements.

The information contained herein does not constitute an offer of securities to
the public in the United Kingdom. No prospectus offering securities to the
public will be published in the United Kingdom. This document is only being
distributed to and is only directed at (i) persons who are outside the United
Kingdom or (ii) to investment professionals falling within article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the
"Order") or (iii) high net worth entities, and other persons to whom it may
lawfully be communicated, falling within article 49(2)(a) to (d) of the Order
(all such persons together being referred to as "relevant persons"). The
securities are only available to, and any invitation, offer or agreement to
subscribe, purchase or otherwise acquire such securities will be engaged in only
with, relevant persons.

Any person who is not a relevant person should not act or rely on this document
or any of its contents. Any offer of securities to the public that may be deemed
to be made pursuant to this communication in any member state of the European
Economic Area (each an "EEA Member State") that has implemented Directive
2003/71/EC (together with the 2010 PD Amending Directive 2010/73/EU, including
any applicable implementing measures in any Member State, the "Prospectus
Directive") is only addressed to qualified investors in that Member State within
the meaning of the Prospectus Directive.

The information contained in this document does not purport to be comprehensive.
None of the Joint Bookrunners, any of their respective subsidiary undertakings
or affiliates, or their respective directors, officers, employees, advisers or
agents accepts any responsibility or liability whatsoever for (whether in
contract, tort or otherwise) or makes any representation or warranty, express or
implied, as to the truth, accuracy or completeness of the information in this
document (or whether any information has been omitted from the document) or any
other information relating to the Company, its subsidiaries, affiliates or
associated companies, whether written, oral or in a visual or electronic form,
and howsoever transmitted or made available or for any loss howsoever arising
from any use of this document or its contents or otherwise arising in connection
therewith. The Joint Bookrunners disclaim any responsibility for any acts or
omissions of the Company, any of the Directors, HealthCap VI L.P. or any other
person in connection with the Private Placement.

The Joint Bookrunners are acting for the Company in connection with the Private
Placement and no one else and will not be responsible to anyone other than the
Company for providing the protections afforded to their respective clients or
for providing advice in relation to the Private Placement or any transaction or
arrangement referred to in this press release.

Solely for the purposes of the product governance requirements contained within:
(a) EU Directive 2014/65/EU on markets in financial instruments, as amended
("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU)
2017/593 supplementing MiFID II; and (c) local implementing measures (together,
the "MiFID II Product Governance Requirements"), and disclaiming all and any
liability, whether arising in tort, contract or otherwise, which any
"manufacturer" (for the purposes of the MiFID II Product Governance
Requirements) may otherwise have with respect thereto, the securities described
in this press release have been subject to a product approval process, which has
determined that such securities are: (i) compatible with an end target market of
retail investors and investors who meet the criteria of professional clients and
eligible counterparties, each as defined in MiFID II; and (ii) eligible for
distribution through all distribution channels as are permitted by MiFID II (the
"Target Market Assessment"). Notwithstanding the Target Market Assessment,
distributors should note that: the price of the securities may decline and
investors could lose all or part of their investment; the securities offer no
guaranteed income and no capital protection; and an investment in the securities
is compatible only with investors who do not need a guaranteed income or capital
protection, who (either alone or in conjunction with an appropriate financial or
other adviser) are capable of evaluating the merits and risks of such an
investment and who have sufficient resources to be able to bear any losses that
may result therefrom. The Target Market Assessment is without prejudice to the
requirements of any contractual, legal or regulatory selling restrictions in
relation to the Transaction. Furthermore, it is noted that, notwithstanding the
Target Market Assessment, the Joint Bookrunners will only approach investors who
meet the criteria of professional clients and eligible counterparties.

For the avoidance of doubt, the Target Market Assessment does not constitute:
(a) an assessment of suitability or appropriateness for the purposes of MiFID
II; or (b) a recommendation to any investor or group of investors to invest in,
or purchase, or take any other action whatsoever with respect to the securities.
Each distributor is responsible for undertaking its own target market assessment
in respect of the securities and determining appropriate distribution channels.

This publication may contain specific forward-looking statements, e.g.
statements including terms like "believe", "assume", "expect", "forecast",
"project", "may", "could", "might", "will" or similar expressions. Such forward
-looking statements are subject to known and unknown risks, uncertainties and
other factors which may result in a substantial divergence between the actual
results, financial situation, development or performance of Nordic Nanovector
and those explicitly or implicitly presumed in these statements. Against the
background of these uncertainties, readers should not rely on forward-looking
statements. Nordic Nanovector assumes no responsibility to update forward
-looking statements or to adapt them to future events or devel

Ekstern link:

Nyheten er levert av OBI.